EVGN:NASDAQEvogene Ltd. Analysis
Data as of 2026-09-25 - not real-time
$0.43
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Evogene Ltd. is priced at $0.4301 and its moving averages line up in bearish order, the shorter trailing the longer. Across the trailing 30 sessions it lost 33.8%. With RSI at 37.2 the momentum picture is approaching oversold, alongside a bearish MACD signal. Watch $0.4175 as support and $0.5600 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 399.9% above the current quote. Revenue is contracting at 60.7%.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 69.9%, a beta of 1.45 and a maximum drawdown of 73.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 399.9% above the current quote. Revenue is contracting at 60.7%.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 69.9%, a beta of 1.45 and a maximum drawdown of 73.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.
Top Market Events
Read Evogene Ltd. EVGN Q2 FY2026 earnings call transcript on Yahoo Finance to keep your investing strategy up to date...Evogene stock remains under pressure, with recent market data showing a modest decline as investorsEvogene stock closed at USD 0.50 on September 18, 2026, with market value at USD 4.35 million. Marke
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.75
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.75
- Analyst targets imply +399.9% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +399.9% versus the current price
- Negative return on equity of -182.7%
- Revenue contracting at -60.7%
Key Metrics & Analysis
Financial Health
Revenue Growth-60.70%
P/E Ratio-0.5
ROE-182.75%
ROA-37.80%
Debt/Equity36.42
P/B Ratio-1.8
Op. Cash Flow$-10947000
Free Cash Flow$-2041250
Industry P/E30.2
Technical Analysis
TrendBearish
RSI37.2
Support$0.42
Resistance$0.56
MA 20$0.50
MA 50$0.54
MA 200$0.75
MACDBearish
VolumeDecreasing
Fear & Greed Index94.45
Valuation
Target Price$2.15
Upside/Downside399.88%
GradeFair
TypeBlend
Risk Assessment
Beta1.45
Volatility69.95%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.